36 records found.
Aug 14, 2019
Heparin Market is Expected to Accumulate Revenues Worth US$16.3 Billion by 2025 - TMR
Aug 05, 2019
New findings provide definitive management guidelines for patients on direct oral anticoagulants with atrial fibrillation undergoing elective procedures or surgeries
Jul 31, 2019
Global Anticoagulants (Xarelto, Eliquis, Pradaxa, Savaysa) Market 2019-2023
Jul 08, 2019
XARELTO® (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study
May 31, 2019
Anticoagulants Market, 2024 - Focus on Oral Anticoagulants & Injectable Anticoagulants (Unfractionated Heparin, & Low Molecular Weight Heparin)
Apr 08, 2019
FDA warns about risks of using home use test strips that are pre-owned or not authorized for sale in U.S., including those for glucose, warfarin
Mar 01, 2019
Anticoagulants - Global Market Outlook to 2024 with Profiles on 48 Players
Feb 01, 2019
FDA warns patients and doctors about recall of home-use test strips used with device to monitor blood thinner warfarin, not authorized for sale in U.S.
Jan 22, 2019
Global Anticoagulants Industry
Dec 14, 2018
Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
Dec 04, 2018
Late-Breaking Clinical Trials Present Clinic-Ready Advances for Non-Malignant Diseases
Oct 31, 2018
Roche Diagnostics to replace CoaguChek® XS PT Test Strips
Oct 11, 2018
U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
Sep 20, 2018
New Survey Reveals People with Atrial Fibrillation Prioritize Stroke Risk Reduction, Seek More Education on Treatment Options
Aug 07, 2018
Global Anticoagulants Market Expected to Reach $43,427 Million by 2025, Says Allied Market Research
Jun 11, 2018
CryoLife Announces Peer Review Publication of On-X® Aortic Heart Valve PROACT Study
May 24, 2018
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
May 16, 2018
Greater Burden of Atrial Fibrillation Linked to Higher Stroke Risk
Apr 17, 2018
FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa
Apr 09, 2018
Houston Methodist The Woodlands Hospital is first hospital in The Woodlands to offer an alternative to long-term warfarin medication to reduce the risk of stroke

Pages